Table 4_The efficacy and safety of colistimethate sodium in the treatment of carbapenem-re

222 patients aged ≥14 years from nine ICUs in Henan Province were enrolled between November 2021 and November 2023. This prospective observational study by Tingyuan Zhang evaluates the clinical efficacy and safety of colistimethate sodium (CMS) for treating carbapenem-resistant Gram-negative bacilli (CR-GNB). The overall clinical response rate was 82.5%, and the 30-day all-cause mortality was 19.8%.

Use Cases

• Modeling risk factors for poor clinical response based on APACHE II scores, infection site, and microbial composition.
• Analyzing the incidence and severity of acute kidney injury (AKI) as a safety endpoint for CMS treatment.
• Comparing clinical efficacy outcomes between subgroups such as single-site vs. multi-site infections.
• Evaluating microbiological response rates (79.0%) and bacterial clearance rates (72.8%) for antibiotic efficacy studies.

Strengths

• Data covers 222 patients from nine ICUs, providing a multi-center perspective.
• Study is prospective and observational, conducted between November 2021 and November 2023.
• Results include specific rates: 82.5% clinical response, 19.8% 30-day mortality, 20.4% AKI incidence.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is limited to ICU patients in Henan Province, China, which may affect generalizability.

Provenance

Source

Tingyuan Zhang

Collection Method

Prospective observational study consecutively enrolling patients from nine ICUs.

Time Range

November 2021 to November 2023

Freshness

Last updated 2026-05-29 04:45:27; freshness should be verified.

Geography

Henan Province, China